Source: Health Products Regulatory Authority (ZA) Revision Year: 2024 Publisher: PHARMACARE LIMITED, Healthcare Park, Woodlands Drive, Woodmead 2191
CYMGEN is contraindicated in:
CYMGEN should not be used within at least 14 days of discontinuing treatment with a MAOI. Based on the half-life of CYMGEN, at least 5 days should be allowed after stopping CYMGEN, before starting a MAOI.
Depression is associated with an increased risk of suicidal thoughts, self-harm, and suicide (suicide-related events). The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Close supervision of patients, and in particular those at high-risk should accompany medicine therapy, especially in early treatment and following dose changes. Cases of suicidal ideation and suicidal behaviours have been reported during CYMGEN therapy or after early treatment discontinuation (see section 4.8).
Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicidal behaviour and should receive careful monitoring during treatment. Reports of antidepressant medicines in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old. In major depressive disorder, there were increased reports of hostility and suicide-related adverse events such as suicidal ideation and self-harm.
Physicians should encourage patients to report any distressing thoughts or feelings at any time. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
CYMGEN should be used cautiously in patients with a history of mania or a diagnosis of bipolar disorder.
CYMGEN should be used cautiously in patients with a history of a seizure disorder.
Mydriasis has been reported in association with duloxetine, as in CYMGEN; therefore, caution should be used when prescribing CYMGEN in patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma.
Increased plasma concentrations of CYMGEN occur in patients with renal impairment or hepatic impairment. A lower starting dose should be used in such patients. An initial dose of 30 mg once daily should be used in patients with renal impairment and those with mild to moderate hepatic impairment (Child-Pugh A and B) (see sections 4.2, 4.3 and 5.2).
Serotonin syndrome, a potentially life-threatening condition, may occur with CYMGEN treatment, particularly with concomitant use of other serotonergic medicines (including SSRIs, SNRIs tricyclic antidepressants or triptans with buprenorphine-containing medicines), with medicines that impair metabolism of serotonin such as MAOIs, or with antipsychotics or other dopamine antagonists that may affect the serotonergic neurotransmitter systems (see sections 4.3 and 4.5).
Serotonin syndrome symptoms may include mental status changes (e.g. agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea).
If concomitant treatment with CYMGEN and other serotonergic medicines that may affect the serotonergic and/or dopaminergic neurotransmitter systems is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
Adverse reactions may be more common during concomitant use of CYMGEN and herbal preparations containing St John’s Wort (Hypericum perforatum) (see section 4.5).
CYMGEN is associated with an increase in blood pressure, and clinically significant hypertension in some patients. This may be due to the noradrenergic effect of duloxetine, as in CYMGEN. Cases of hypertensive crisis have been reported with duloxetine, as in CYMGEN, especially in patients with pre-existing hypertension. Therefore, in patients with known hypertension and/or other cardiac disease, blood pressure monitoring is recommended as appropriate, especially during the first month of treatment.
CYMGEN should be used with caution in patients whose conditions could be compromised by an increased heart rate or by an increase in blood pressure. Caution should also be exercised when duloxetine, as in CYMGEN, is used with medicines that may impair its metabolism (see section 4.5). For patients who experience a sustained increase in blood pressure while receiving duloxetine, as in CYMGEN, either dose reduction or gradual discontinuation should be considered (see section 4.8). In patients with uncontrolled hypertension, CYMGEN should not be initiated.
Severe elevations of liver enzymes (>10 times the upper limit of normal) or liver injury with a cholestatic or mixed pattern, hepatitis, and jaundice have been reported with duloxetine, as in CYMGEN (see section 4.8). These were usually transient and self-limiting, or resolved upon discontinuation of CYMGEN. Most of these occurred during the first months of treatment. The pattern of liver damage was predominantly hepatocellular. It is in some cases associated with excessive alcohol use or pre-existing liver disease, CYMGEN should be used in caution in patients with substantial alcohol use, in patients with pre-existing liver disease or in patients treated with other medicines associated with hepatic injury.
SSRIs/SNRIs such as duloxetine, as in CYMGEN, may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI such as duloxetine, as in CYMGEN.
Duloxetine, as in CYMGEN, was administered in the diet to rats and mice for 2 years. In rats, duloxetine, as in CYMGEN, did not cause any increase in incidence of expected or unusual neoplasms or decrease in the latency for any tumour type. In female mice receiving duloxetine, as in CYMGEN, there was an increased incidence of hepatocellular adenomas and carcinomas at the high dose only (144 mg/kg/day), but these were considered to be secondary to hepatic enzyme induction with associated centrilobular hypertrophy and vacuolation. The relevance of this data in humans is unknown.
Duloxetine, as in CYMGEN, has demonstrated no mutagenic potential in a battery of in vitro and in vivo genotoxicity tests.
Reproductive performance was not affected in male rats receiving duloxetine, as in CYMGEN (45 mg/kg/day). In female rats receiving duloxetine, as in CYMGEN (45 mg/kg/day), reproductive toxicity was demonstrated by a decrease in maternal food consumption and body weight, oestrous cycle disruption, depression in live birth indices and progeny survival and progeny growth retardation. The no-observed-effect level (NOEL) for maternal toxicity, reproductive toxicity and developmental toxicity in the female fertility study was 10 mg/kg/day. The relevance of this preclinical data in humans is unknown (see section 4.6).
Literature shows an association between increased levels of catecholamines and the risk of Takotsubo cardiomyopathy, suggesting that inhibition of androgen receptors by duloxetine results in increased catecholamines levels and consequently cardiomyopathy. Takotsubo cardiomyopathy is reversible upon discontinuation of CYMGEN and appropriate treatment.
CYMGEN, may increase the risk of bleeding events, such as ecchymoses, purpura, and gastrointestinal bleeding (see section 4.8). CYMGEN may increase the risk of postpartum haemorrhage (see sections 4.6 and 4.8). Therefore, caution is advised in patients taking CYMGEN concomitantly with anticoagulants and/or medicines known to affect platelet function (e.g. NSAIDs or aspirin), and in patients with known bleeding tendencies (see section 4.5).
Hyponatraemia has been reported when administering duloxetine, as in CYMGEN, including cases with serum sodium lower than 110 mmol/L. Hyponatraemia may be due to a syndrome of inappropriate anti-diuretic hormone secretion (SIADH) (see section 4.8). The majority of cases of hyponatraemia were reported in the elderly, especially when coupled with a recent history of, or condition pre-disposing to, altered fluid balance. Caution is required in patients at increased risk for hyponatraemia, such as elderly, cirrhotic or dehydrated patients, or patients treated with diuretics.
Hyponatraemia may present with nonspecific signs and symptoms (such as dizziness, weakness, nausea, vomiting, confusion, somnolence, and lethargy). Signs and symptoms associated with more severe cases have included syncopal episodes, falls and seizure.
Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see sections 4.2 and 4.8). Adverse events seen on abrupt treatment discontinuation have been reported. They occurred in approximately 45 % of patients treated with duloxetine, as in CYMGEN, and 23 % of patients taking placebo.
The risk of withdrawal symptoms seen with SSRIs and SNRIs such as duloxetine, as in CYMGEN, may be dependent on several factors, including the duration and dose of therapy and the rate of dose reduction. The most commonly reported reactions are listed in section 4.8. Generally, these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been reports of such symptoms in patients who have inadvertently missed a dose. Generally, these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2 to 3 months or more). It is therefore advised that CYMGEN should be gradually tapered when discontinuing treatment over a period of no less than 2 weeks, according to the patient’s needs (see section 4.2).
The use of CYMGEN has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness, and need to move, often accompanied by an inability to sit or stand still (see section 4.8). This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.
Data on the use of CYMGEN 120 mg in elderly patients with depression are limited. Therefore, caution should be exercised when treating the elderly with the maximum dosage (see sections 4.2 and 5.1).
CYMGEN is contraindicated for use in patients under 18 years of age (see sections 4.3 and 4.8). Duloxetine, should not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempts and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour, and anger) were more frequently observed among children, adolescents, and young adults (<25 years of age) treated with antidepressants such as duloxetine, compared to those treated with placebo. In addition, long-term safety data in children and adolescents concerning growth, maturation, and cognitive and behavioural development are lacking.
CYMGEN contains sucrose.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Due to the risk of serotonin syndrome, CYMGEN should not be used in combination with non-selective, irreversible monoamine oxidase inhibitors (MAOIs) including linezolid and moclobemide or within at least 14 days of discontinuing treatment with a MAOI. Based on the half-life of CYMGEN, at least 5 days should be allowed after stopping CYMGEN, before starting a MAOI (see sections 4.3 and 4.4).
In a clinical study, the pharmacokinetics of theophylline, a CYP1A2 substrate, were not significantly affected by co-administration with duloxetine, as in CYMGEN, (60 mg twice daily). These results suggest that duloxetine, as in CYMGEN, is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.
Because CYP1A2 is involved in duloxetine, as in CYMGEN, metabolism, concomitant use of duloxetine, as in CYMGEN, with inhibitors of CYP1A2 will result in higher concentrations of duloxetine, as in CYMGEN. Fluvoxamine (100 mg once daily), a potent inhibitor of CYP1A2, decreased the apparent plasma clearance of duloxetine, as in CYMGEN, by about 77 % and increased AUCo-t 6-fold. Therefore, duloxetine, as in CYMGEN, should not be administered in combination with potent inhibitors of CYP1A2 like fluvoxamine. Caution is advised if administering duloxetine, as in CYMGEN, with inhibitors of CYP1A2 (e.g. quinolone antibiotics) and a lower duloxetine, as in CYMGEN, dose should be used.
Duloxetine, as in CYMGEN, is a moderate inhibitor of CYP2D6. When duloxetine, as in CYMGEN, was administered at the dose of 60 mg twice daily with a single dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine, as in CYMGEN (40 mg twice daily) increased the steady-state AUC of tolterodine (2 mg twice daily) by 71% but did not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is recommended. Therefore, caution should be used if duloxetine, as in CYMGEN, is co-administered with medicines that are predominately metabolised by the CYP2D6 (risperidone, tricyclic antidepressants (TCAs), such as nortriptyline, amitriptyline, and imipramine), particularly if they have a narrow therapeutic index (such as flecainide, propafenone, and metoprolol).
Because CYP2D6 is involved in CYMGEN metabolism, concomitant use of CYMGEN with inhibitors of CYP2D6 may result in higher concentrations of CYMGEN. Paroxetine (20 mg once daily) decreased the apparent plasma clearance of CYMGEN by about 37 %. Caution is advised if administering CYMGEN with inhibitors of CYP2D6 (e.g. SSRIs).
The risk of using duloxetine, as in CYMGEN, in combination with other CNS-active medicines has not been systematically evaluated, except in the cases described in this section. Consequently, caution is advised when duloxetine, as in CYMGEN, is taken in combination with other centrally acting medicines and substances, including alcohol and sedative medicines (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbitone, sedative antihistamines).
Serotonin syndrome has been reported in patients using SSRIs/SNRIs such as duloxetine, as in CYMGEN, concomitantly with serotonergic medicines. Caution is advised if duloxetine, as in CYMGEN, is used concomitantly with serotonergic medicines like SSRIs, SNRIs, tricyclics antidepressants like clomipramine or amitriptyline, MAOIs like moclobemide or linezolid, St John’s Wort (Hypericum perforatum) or triptans, tramadol, pethidine, and tryptophan (see sections 4.3 and 4.4).
CYMGEN should be used cautiously when co-administered with buprenorphine-containing medicines as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).
Results of in vitro studies demonstrate that duloxetine, as in CYMGEN, does not induce the catalytic activity of CYP3A. Specific in vivo medicine interaction studies have not been performed.
Caution should be exercised when CYMGEN is combined with oral anticoagulants or antiplatelet medicines due to a potential increased risk of bleeding attributable to a pharmacodynamic interaction (see section 4.4). Furthermore, increases in INR values have been reported when duloxetine, as in CYMGEN, was co-administered to patients treated with warfarin. However, concomitant administration of duloxetine, as in CYMGEN, with warfarin under steady state conditions, in healthy volunteers, as part of a clinical pharmacology study, did not result in a clinically significant change in INR from baseline or in the pharmacokinetics of R- or S-warfarin.
Co-administration of duloxetine, as in CYMGEN, with aluminium-and magnesium-containing antacids, or duloxetine, as in CYMGEN, with famotidine, had no significant effect on the rate or extent of duloxetine, as in CYMGEN, absorption after administration of a 40 mg oral dose.
Population pharmacokinetic analyses have shown that smokers have almost 50% lower plasma concentrations of duloxetine, as in CYMGEN, compared with non-smokers.
CYMGEN is highly bound to plasma proteins (>90%). Therefore, administration of CYMGEN to a patient taking another medicine that is highly protein bound may cause an increase in free concentration of either medicine.
Safety in pregnant women has not been established.
CYMGEN should not be used during pregnancy. Discontinuation symptoms (e.g. hypotonia, tremor, jitteriness, feeding difficulty, respiratory distress and seizures) may occur in the neonate after maternal CYMGEN use near term (see section 4.3). The majority of cases have occurred either at birth or within a few days of birth.
Studies in animals have shown reproductive toxicity at systemic exposure levels (AUC) of duloxetine, as in CYMGEN, lower than the maximum clinical exposure.
Two large observational studies do not suggest an overall increased risk of major congenital malformation (one from the US including 2,500 exposed to duloxetine, as in CYMGEN, during the first trimester and one from the EU including 1,500 exposed to duloxetine, as in CYMGEN, during the first trimester). The analysis on specific malformations such as cardiac malformations show inconclusive results.
In the EU study, maternal exposure to duloxetine, as in CYMGEN, during late pregnancy (at any time from 20 weeks gestational age to delivery) was associated with an increased risk for pre-term birth (less than 2-fold, corresponding to approximately 6 additional premature births per 100 women treated with duloxetine, as in CYMGEN, late in pregnancy). The majority occurred between 35 and 36 weeks of gestation.
Observational data indicated an increased risk (less than 2-fold) of postpartum haemorrhage following duloxetine, as in CYMGEN, exposure within the month prior to birth (see sections 4.4 and 4.8).
Epidemiological data have suggested that the use of SSRIs, such as duloxetine, as in CYMGEN, in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated the association of PPHN to SNRI treatment, this potential risk cannot be ruled out with CYMGEN, taking into account the related mechanism of action (inhibition of the re-uptake of serotonin).
The safety of CYMGEN has not been established in breastfeeding women. CYMGEN is excreted into the milk of lactating women. The estimated daily infant dose on a mg/kg basis is approximately 0,14 % of the maternal dose. Because the safety of CYMGEN in infants is not known, the use of CYMGEN while breastfeeding is not recommended (see section 4.3).
In animal studies, duloxetine, as in CYMGEN, had no effect on male fertility, and effects in females were only evident at doses that caused maternal toxicity.
CYMGEN has minor influence on the ability to drive or operate machinery. Since adverse reactions such as sedation and dizziness have been reported in patients receiving CYMGEN, patients should not drive, use machinery or perform any tasks that require concentration, until they are certain that CYMGEN does not adversely affect their ability to do so (see section 4.8).
The most commonly reported adverse reactions in patients treated with duloxetine, as in CYMGEN, were nausea, headache, dry mouth, somnolence and dizziness. However, the majority of common adverse reactions were mild to moderate; they usually started early in therapy, and most tended to subside even as therapy was continued.
The table below gives the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials for duloxetine as contained in CYMGEN.
| System organ class | Frequent | Less frequent | Frequency unknown (cannot be estimated from the available data) |
|---|---|---|---|
| Infections and infestations | Laryngitis. | ||
| Immune system disorders | Anaphylactic reaction, hyper-sensitivity disorder | ||
| Endocrine disorders | Hypothyroidism. | ||
| Metabolism and nutrition disorders | Decreased appetite11 (includes anorexia. Previously listed under anorexia and decreased appetite, or anorexia and appetite decreased). | Dehydration, hyperglycaemia (reported especially in diabetic patients), hyponatraemia, Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH)6 | |
| Psychiatric disorders | Insomnia (also includes middle insomnia, early morning awakening, and initial insomnia), abnormal orgasm (also includes anorgasmia), libido decreased (also includes loss of libido), anxiety, sleep disorder, agitation (also includes feeling jittery, nervousness, restlessness, tension and psychomotor agitation)6 abnormal dreams (includes nightmares), MDD only | Bruxism, disorientation (includes confusional state) apathy, suicidal ideation,5,7 suicidal behaviour,5,7 hallucinations, mania, aggression and anger.4 | |
| Nervous system disorders | Headache (placebo rate was more than duloxetine rate), dizziness, lethargy, somnolence11 (also includes hypersomnia, sedation) tremor, dysgeusia, paraesthesia (includes hypoaesthesia, hypoaesthesia facial, and paraesthesia oral). | Disturbance in attention, dyskinesia, poor quality sleep, myoclonus, akathisia,6 restless leg syndrome, convulsions1,6,11 (seizures,11), extrapyramidal symptoms,6 serotonin syndrome,6,11 | |
| Eye disorders | Vision blurred. | Mydriasis, Visual impairment, glaucoma. | |
| Ear and labyrinth disorders | Tinnitus.1 | Vertigo, ear pain. | |
| Cardiac disorders | Palpitations. | Tachycardia,11 supra- ventricular dysrhythmia, mainly atrial fibrillation, Takotsubo cardiomyopathy. | |
| Vascular disorders | Blood pressure increase (includes blood pressure systolic diastolic increased, systolic hypertension, diastolic hypertension, essential hypertension),3 flushing | Peripheral coldness, orthostatic hypotension,2 hypertension,3,7 hypertensive crisis.3,6 Syncope.2 | |
| Respiratory, thoracic and mediastinal disorders | Yawning. | Throat tightness, epistaxis. interstitial lung disease,10 eosinophilic pneumonia.6 | |
| Gastrointestinal disorders | Constipation, dry mouth, nausea, diarrhoea, vomiting,11 abdominal pain, dyspepsia (includes stomach discomfort), flatulence. | Eructation, gastroenteritis, stomatitis, breath odour, gastritis, gastrointestinal haemorrhage,7 dysphagia, haematochezia, microscopic colitis.9 | |
| Hepatobiliary disorders | Hepatitis,3 acute liver injury, hepatic failure,6 jaundice.6 | ||
| Skin and subcutaneous tissue disorders | Hyperhidrosis, rash. | Night sweats, photosensitivity reaction, cold sweat, dermatitis contact, urticaria, increased tendency to bruise, Stevens-Johnson Syndrome (SJS),6 angio-neurotic oedema,6 cutaneous vasculitis, | |
| Musculoskeletal and connective tissue disorders | Musculoskeletal pain (includes myalgia and neck pain), muscle spasm. | Muscle tightness (includes musculoskeletal stiffness), muscle twitching, trismus. | |
| Renal and urinary disorders | Pollakiuria, dysuria. | Nocturia, urinary hesitation, urinary retention, polyuria, urine flow decreased, urine odour abnormal. | |
| Reproductive system and breast disorders | Erectile dysfunction, ejaculation disorder (also includes ejaculation failure and ejaculation dysfunction), ejaculation delayed. | menopausal symptoms, sexual dysfunction, gynaecological haemorrhage, menstrual disorder, testicular pain, galactorrhoea, hyper-prolactinaemia, postpartum haemorrhage.6 | |
| General disorders and administrative site conditions | Fatigue (also includes asthenia), abdominal pain (includes abdominal pain upper, abdominal pain lower, abdominal tenderness, abdominal discomfort and gastrointestinal pain), falls.8 | Feeling abnormal, feeling cold, feeling hot, malaise, thirst, gait disturbance, chest pain.7 chills. | |
| Investigations | Weight decreased | Hepatic lab related findings (includes alanine aminotransferase increased, hepatic enzyme increased, aspartate aminotransferase increased, liver function test abnormal, gamma- glutamyl transferase increased, blood alkaline phosphatase increased, blood bilirubin increased), weight increased, blood cholesterol increased, blood creatine phosphokinase increased, blood potassium increased. |
1 Cases of convulsion and cases of tinnitus have also been reported after treatment discontinuation.
2 Cases of orthostatic hypotension and syncope have been reported especially at the initiation of treatment.
3 See section 4.4
4 Cases of aggression and anger have been reported particularly early in treatment or after treatment discontinuation.
5 Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine, as in CYMGEN, therapy or early after treatment discontinuation (see section 4.4).
6 Estimated frequency of post-marketing surveillance reported adverse reactions; not observed in placebo-controlled clinical trials.
7 Not statistically significantly different from placebo.
8 Falls were more common in the elderly (≥ 65 years old)
9 Estimated frequency based on all clinical trial data
10 Estimated frequency based on placebo-controlled clinical trials.
11 Signs and symptoms of overdose with CYMGEN alone or with mixed medicines.
Discontinuation symptoms: Discontinuation of duloxetine, as in CYMGEN, (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia or electric shock-like sensations, particularly in the head), sleep disturbances (including insomnia and intense dreams, nightmares), fatigue, somnolence, agitation or anxiety, nausea and/or vomiting, tremor, headache, myalgia, irritability, diarrhoea, hyperhydrosis and vertigo are the most commonly reported withdrawal symptoms.
Generally, for SSRIs and SNRIs such as duloxetine, as in CYMGEN, events are mild to moderate and self-limiting; however, in some patients these may be severe and/or prolonged. It is therefore advised that when duloxetine, as in CYMGEN, treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).
Duloxetine, as in CYMGEN, treatment in placebo-controlled clinical trials was associated with mean increases from baseline to endpoint in ALT, AST, CPK and potassium. In some cases, abnormal values were observed for these analytes in duloxetine, as in CYMGEN, treated patients. The heart rate-corrected QT interval in duloxetine, as in CYMGEN-treated patients did not differ from that seen in placebo-treated patients. No clinically significant differences were observed for QT, PR, QRS, or QTcB measurements between duloxetine, as in CYMGEN-treated and placebo-treated patients.
In three clinical trials of CYMGEN for the treatment of diabetic peripheral neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine, as in CYMGEN-treated patients. HbA1c was stable in both duloxetine, as in CYMGEN-treated and placebo-treated patients. The mean duration of diabetes was approximately 12 years, the mean baseline fasting blood glucose was 9,048 mmol/L (176 mg/dl), and the mean baseline haemoglobin A1c (HbA1c) was 7,81 . In the 12-week acute treatment phase of these studies, small increases in fasting blood glucose were observed in duloxetine, as in CYMGEN-treated patients. HbA1c was stable in both the duloxetine-treated and placebo-treated patients. In the extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA1c in both the duloxetine, as in CYMGEN, and the routine care groups, but the mean increase was 0,3 greater in the duloxetine, as in CYMGEN-treated group. There was also a small increase in fasting blood glucose and in total cholesterol in duloxetine, as in CYMGEN-treated patients while those laboratory tests showed a slight increase in the routine care group.
CYMGEN is contraindicated in patients under 18 years of age (see section 4.3). In children there have been reports of hostility, suicidal ideation and self-harm (see section 4.4).
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the “6.04 Adverse Drug Reactions Reporting Form”, found online under SAHPRA’s publications: https://www.sahpra.org.za/Publications/Index/8
Aspen Pharmacare:
E-mail: Drugsafety@aspenpharma.com
Tel: 0800 118 088/ +27 (0)11 239-6200
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.